Echoiq Ltd
Research Echoiq Ltd (EIQ) on Bullrun: market cap AUD 1.14B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerEIQ
- ExchangeAU
- CountryAustralia
- SectorHealthcare
- IndustryHealth Information Services
- CurrencyAUD
- Market capAUD 1.14B
- Financial periodFY2025
Valuation Snapshot
latest market cap is AUD 1.14B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | n/a | n/a | n/a | n/a | -0.02 | n/a | n/a | n/a |
| FY2024 | AUD 44.50K | -AUD 5.41M | -AUD 4.01M | 100.0% | -0.01 | AUD 2.12M | n/a | AUD 6.77M |
| FY2023 | AUD 107.33K | -AUD 7.80M | -AUD 5.28M | 100.0% | -0.02 | AUD 3.28M | n/a | AUD 7.44M |
| FY2022 | AUD 251.10K | -AUD 5.67M | -AUD 3.18M | 100.0% | -0.02 | AUD 2.41M | n/a | AUD 7.84M |
| FY2021 | AUD 983.18K | -AUD 2.98M | -AUD 1.42M | 100.0% | n/a | AUD 3.81M | n/a | AUD 9.32M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-24 | AUD 1.14B | n/a | n/a | n/a |
About Echoiq Ltd
Echo IQ Limited engages in the provision of artificial intelligence (AI) diagnostics tool that enhance the diagnosis of structural heart disease in Australia. It offers EchoSolv, provides an AI-powered risk assessment of structural heart disease, including aortic stenosis, diastolic dysfunction, and heart failure. The company has a research collaboration with Mayo Clinic to evaluate echo IQ's proprietary artificial intelligence platform for cardiac risk stratification in oncology patients.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Echoiq Ltd's market cap?
Echoiq Ltd's market capitalization is AUD 1.14B.
What does Echoiq Ltd do?
Echo IQ Limited engages in the provision of artificial intelligence (AI) diagnostics tool that enhance the diagnosis of structural heart disease in Australia. It offers EchoSolv, provides an AI-powered risk assessment of structural heart disease, including aortic stenosis, diastolic dysfunction, and heart failure. The company has a research collaboration with Mayo Clinic to evaluate echo IQ's proprietary artificial intelligence platform for cardiac risk stratification in oncology patients.